Inhibition of Corneal Neovascularization with the Combination of Bevacizumab and Plasmid Pigment Epithelium-Derived Factor-Synthetic Amphiphile INTeraction-18 (p-PEDF-SAINT-18) Vector in a Rat Corneal Experimental Angiogenesis Model

Bevacizumab, a 149-kDa protein, is a recombinant humanized monoclonal antibody to VEGF. PEDF, a 50-kDa glycoprotein, has demonstrated anti-vasopermeability properties. In this study, we demonstrated that the combination of bevacizumab and plasmid pigment epithelium-derived factor-synthetic amphiphil...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Chien-Neng, Chen, Chung-Yi, Chen, San-Ni, Yang, Lin-Cheng, Lai, Li-Ju, Lai, Chien-Hsiung, Chen, Miao-Fen, Hung, Chia-Hui, Chen, Ching-Hsein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645743/
https://www.ncbi.nlm.nih.gov/pubmed/23591843
http://dx.doi.org/10.3390/ijms14048291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645743/
https://www.ncbi.nlm.nih.gov/pubmed/23591843
http://dx.doi.org/10.3390/ijms14048291

Ejemplares similares